Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review

Matthieu Lavielle,1,2 Déborah Puyraimond-Zemmour,3 Xavier Romand,4 Laure Gossec,5,6 Eric Senbel,6 Sophie Pouplin,7 Catherine Beauvais,8 Loriane Gutermann,9 Maryse Mezieres,1 Maxime Dougados,1,2,10 Anna Molto1,2,10

ABSTRACT

Objective Lack of adherence to treatment is frequent in chronic inflammatory rheumatic diseases and is associated with poorer outcomes. The objective of this study was to describe and evaluate interventions that have been proposed to enhance medication adherence in these conditions.

Methods A systematic literature review was performed in Pubmed, Cochrane, Embase and clinicaltrials.gov databases completed by the rheumatology meeting (ACR, EULAR and SFR) abstracts from last 2 years. All studies in English or French evaluating an intervention to improve medication adherence in chronic inflammatory rheumatic diseases (rheumatoid arthritis (RA), spondyloarthritis (SpA), crystal related diseases, connective tissue diseases, vasculitis and Still’s disease) were included. Interventions on adherence were collected and classified in five modalities (educational, behavioural, cognitive behavioural, multicomponent interventions or others).

Results 1325 abstracts were identified and 22 studies were finally included (18 studies in RA (72%), 4 studies in systemic lupus erythematosus (16%), 2 studies in SpA (8%) and 1 study in gout (4%)). On 13 randomised controlled trials (RCT) (1535 patients), only 5 were positive (774 patients). Educational interventions were the most represented and had the highest level of evidence: 8/13 RCT (62%, 1017 patients) and 4/8 were positive (50%). In these studies, each patient was individually informed or educated by different actors (physicians, pharmacists, nurses and so on). Supports and contents of these educational interventions were heterogenous.

Conclusion Despite the importance of medication adherence in chronic inflammatory rheumatic disorders, evidence on interventions to improve medication adherence is scarce.

Key messages

What is already known about this subject?► Medication non-adherence in chronic inflammatory rheumatic diseases is associated with poorer outcomes and important costs.

What does this study add?► This systematic literature review reports that educational interventions do improve medication adherence in these conditions and have the highest level of evidence.

How might this impact on clinical practice?► Educational interventions can be proposed to patients suffering of chronic inflammatory rheumatic diseases in order to optimise their medication adherence.

► Other types of interventions might be added but they need further good quality evaluation.

INTRODUCTION

Adherence to long-term therapy can be defined by the extent to which a person’s behaviour—taking medication, following a diet and/or executing lifestyle changes—corresponds with agreed recommendations from a healthcare provider.

It is a dynamic process in which the patient is involved to actively participate. It can be explained as a combination of the term ‘compliance’ which means ‘taking the right dose at the right time’ and the term ‘persistence’ which means ‘taking the treatment continuously during the period of time prescribed’. However, we have to make the distinction between medication adherence and retention rate, which is a more complex notion often used as a surrogate effectiveness measure in observational studies (eg, registries). In the majority of studies, good adherence has been defined as taking 80% or more of the designated medication over the duration of the study.

Promoting adherence to treatment in chronic inflammatory rheumatic diseases is a critical yet challenging task for healthcare providers. First of all, lack of adherence is
frequent in these diseases. For instance in RA, non-adherence can reach 20%–50% of all prescriptions. Furthermore, it has been shown that poor adherence is associated with poor outcomes in chronic diseases. In a recent article of the New York Times, lack of adherence was shown to be responsible for 125,000 deaths per year in the USA. In the same article, direct and indirect costs due to non-adherence were evaluated up to 100–289 billions of dollars in the USA. In RA, non-adherence is associated with a higher disease activity (DAS 28 and HAQ) which could lead to an increase of costs because of uncontrolled disease which may induce intensification of the treatment strategy. In view of the multiple negative implications of non-adherence, effective interventions to improve medication adherence are warranted.

Several modalities of interventions can be proposed in order to enhance medication adherence and can be classified in 4 categories: educational, behavioural, cognitive and multicomponent interventions. Educational interventions aim to enhance patient knowledge of the disease, the benefits and mechanisms of action of the medication regimen, the consequences of non-adherence and potential side effects of treatment. Behavioural interventions promote the act of medication taking and/or reinforce adherence by providing incentives for medication taking. Cognitive behavioural interventions intend to enhance adherence by modifying patients’ thinking patterns that contribute to non-adherence while also establishing behavioural patterns that support adherence using aforementioned behavioural strategies. Based on motivational interviewing, these strategies explore the ambivalence between necessity beliefs and concern beliefs (fear of potential adverse events) in order to make the patient realise that taking the medication will improve his health. Finally, multicomponent interventions use multiple strategies to enhance adherence.

The objective of the present study was to describe the interventions that have been proposed to improve medication adherence in chronic inflammatory rheumatic diseases and to assess their efficacy.

METHODS
Systematic literature search and selection of the relevant studies
We performed a systematic review of the literature according to the Cochrane guidelines.

Relevant publications were selected using PubMed, Embase and Cochrane databases without time limitation (up to February 2017). Associations of key words around the disease names and ‘medication adherence’ or ‘patient compliance’ were used (online supplementary table 1).

The search was completed by hand search using the references of the most relevant studies provided by the initiative’s scientific committee of experts in the field. For unpublished data, a search to the American College of Rheumatology (ACR), European League against Rheumatism (EULAR) and French Society of Rheumatology (SFR) meeting abstracts of the past 2 years was made (2016–2017) completed by a search on Clinicaltrials.gov.

To select the relevant studies first on abstracts then on full texts, we established the following inclusion criteria: adult, studies published in English or in French, diseases considered were: rheumatoid arthritis (RA), spondyloarthritis (SpA) including psoriatic arthritis (PsA), connective tissue diseases including systemic lupus erythematosus (SLE), crystal related diseases including gout and chondrocalcinosis, vasculitis including ANCA associated vasculitis, giant cell arteritis and polymyalgia rheumatica and Still’s disease. Pharmacological medications considered were: conventional synthetic disease modifying antirheumatic drugs, biological DMARDs, immunosuppressive drugs (cyclophosphamide, among others), non-steroidal anti-inflammatory drugs, corticosteroids, colchicine and urate-lowering therapy. All design of studies assessing an intervention with the objective to enhance medication adherence were accepted. Reviews were not included.

The flowchart shows this selection process (figure 1).

Data extraction
We collected data regarding the design of the studies: randomised or non-randomised, controlled or not, length of follow-up, number of patients in each group (intervention and control). Characteristics of the population were also collected: disease studied, disease duration, activity of the disease, age at baseline, gender, treatment studied. We then collected information on the intervention under evaluation: type of intervention aiming to improve medication adherence (educational, among others), main components and supports of this intervention, actors of the intervention, patients targeted by the intervention (systematic for all patients or targeted on patients considered to be non-adherent or at high risk of non-adherence). Tools used to measure adherence were noticed and finally, results on adherence were collected in each group of patient if available.

Analysis of the results
Effect sizes were not calculated due to the heterogeneity of the design of the majority of selected studies, that is, results were not pooled in a meta-analysis given the different adherence measures across studies. Results were then presented individually study by study.

RESULTS
Literature search and characteristics of included studies
According to the key words and after screening 1325 publications, 22 studies were finally included in the review (13 randomised controlled trials (RCT) (1535 patients) and 9 non-randomised studies (2397 patients)).

The flowchart shows the selection process (figure 1).

We selected 18 studies in RA (72%), 4 studies in SLE (16%), 2 studies in SpA (8%) and 1 study in gout (4%). Educational interventions were the most represented in the selected studies: 11 studies (8 RCTs (1017 patients), 3 non-randomised studies (962 patients). Only 2 studies...
Figure 1  Flowchart of the selection process. ACR, American College of Rheumatology; EULAR, European League against Rheumatism; SFR, French Society of Rheumatology.

Educational interventions

Educational interventions were the most represented in the selected studies, and 6/11 studies were positive (table 1).

Among the eight selected RCTs, Hill et al reported that patients with RA who received a 6-month repeated education program given by a nurse and based on oral and written information on the disease and the treatment were more adherent to D-penicillamine than control patients. In another RCT on RA, patients who received an individual education using audio-visual supports (2 × 10 min) were more adherent to their treatment at 6 months (methotrexate, sulfasalazine, hydroxychloroquine (HCQ) ± corticosteroids) than patients from the control group. In a third RCT focused on multiple chronic diseases including RA, a phone call given by a pharmacist 2 weeks after recruitment in order to provide information and counselling to the patient improved adherence to treatment at 4 weeks by comparison with usual care. Last positive RCT was performed in SLE.

This study showed that targeted nursing by specialised nurses including an education during the hospitalisation, a personalised treatment plan and a follow-up after the hospital was better to improve adherence than regular specific nursing. However, these positive results were in balance with three RCTs which showed negative results: two of them assessed the efficacy of repeated collective education program in RA and the other proposed a multimedia support to educate RA patients.

Homer et al compared individual education to collective education in a RCT, and found no difference between the two modes of educational intervention.

Among the non-randomised selected studies, in a longitudinal cohort study, Stockl et al showed that a RA disease therapy management program including repeated phone consultations by a pharmacist or by a nurse providing education associated with a mail service medication delivery, refill reminders by patient care coordinators and access to a pharmacist 24 hours a day, 7 days a week improved medication adherence to injectable RA medications by comparison with usual care. In a pilot study in gout, subjects completed a gout self-management knowledge examination at enrolment, 6 and 12 months. Each examination was followed by a nursing structured educational intervention and structured monthly follow-up calls from pharmacists emphasised adherence to management programs. Morisky’s compliance scores improved from median baseline score at 6
| Author                  | Condition                  | Study design | Type of intervention/Adherence assessment                                      | Result                                                                                                                                 |
|-------------------------|----------------------------|--------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Hill et al, 2001        | RA                         | RCT, 6 months | Educational vs usual care Pharmacological marker                               | At 6 months, 85% of the IG compared with 55% of the CG were taking their medication as prescribed (p<0.05)                              |
| Ravindran and Jadhav, 2013 | RA                        | RCT, 6 months | Educational vs usual care Morisky (MMAS-8)                                     | At 6 months, 98% of the IG were adherent compared with 83% in the CG (p=0.0003)                                                        |
| Clifford et al, 2006    | Multiple chronic diseases including RA | RCT, 1 month | Educational vs usual care Patient report by phone                               | At 1 month, 91% of the IG were adherent compared with 84% in the CG (p=0.032)                                                         |
| Zhang et al, 2016       | SLE                        | RCT, 20 months | Educational vs usual care Likert scale (10 items, max=20 points)               | At 20 months, mean adherence score was 15.6 in the IG compared with 7.7 in the CG (p=0.033)                                             |
| Brus et al, 1998        | RA                         | RCT, 12 months | Educational vs usual care Pharmacy data                                       | No significant difference between IG and CG                                                                                           |
| Helliwell et al, 1999  | RA                         | RCT, 12 months | Educational vs usual care Morisky (MMAS-4)                                     | No significant difference between IG and CG                                                                                           |
| Unk, 2014               | RA                         | RCT, 1 month  | Educational vs usual care MAQ                                                 | No significant difference between IG and CG                                                                                           |
| Homer et al, 2009       | RA and PsA                 | RCT          | Individual education vs collective education Patient self-report and pill counts | No significant difference between the two types of educational interventions                                                           |
| Stockl et al, 2010      | RA                         | Longitudinal cohort study, 6 months | Educational vs usual care PDC                                               | At 6 months, mean PDC was 89% in the IG compared with 60% in the CG (p<0.001)                                                        |
| Fields et al, 2017      | Gout                       | Single arm prospective non-controlled study, 12 months | Educational Morisky (MMAS-4)                                               | Morisky scores improved from median baseline score at 6 months and minimally further increased at 12 months                        |
| Van der Vaart et al, 2014 | RA                       | Non-randomised controlled study, 5 months | Educational vs usual care Morisky (MMAS)                                   | No significant difference between website users and non users                                                                      |
| Ting et al, 2012        | SLE                        | RCT, 14 months | Behavioural vs usual care Patient self-report, HCQ blood levels and pharmacy refill data | No significant difference between IG and CG                                                                                           |
| Bruera et al, 2014      | RA                         | Prospective cohort study | Behavioural CQR                                                             | Use of reminders was associated with better adhesion especially in situations at high risk to forget the treatment                   |
| Evers et al, 2002       | RA                         | RCT, 12 months | Cognitive behavioural vs usual care Self report (3 points scale)              | At 12 months, significative increase in medication adherence in IG (p<0.05 baseline vs M12) Trend to decrease in medication adherence in CG (p<0.08) |
| Zwikker et al, 2014     | RA                         | RCT, 12 months | Cognitive behavioural vs usual care CQR, MARS and pharmacy refill data        | No significant difference between IG and CG                                                                                           |
months and minimally further increased at 12 months. In a non-randomised study, RA patients using an information/education website were not more adherent to their treatment than non-users.

**Behavioural interventions**

We only found one RCT evaluating a behavioural intervention. This study assessed the effects of cellular text messaging reminders on adherence to HCQ in patients with SLE and was negative.

In a prospective cohort study, investigators looked at the use of medication reminders such as pill containers, calendars or diaries in patients with RA. They found a positive association between using those reminders and a good adherence to treatment especially in situations with a high risk to forget to take the treatment: while away from home, when busy and when running out of pills (table 1).

**Cognitive behavioural interventions**

We only found one positive study on a cognitive behavioural intervention, a RCT in which patients allocated to the intervention arm received a cognitive behavioural therapy within 6 months, consisting in total 10 biweekly, 1 hour sessions and 1 final booster session scheduled 4 weeks later and were compared to a control group of patients who received usual care. This intervention was not systematic but targeted on patients being considered at high psychosocial risk. The cognitive behavioural therapy consisted of individual treatment with two of the four possible treatment modules that targeted the most frequently experienced problems with which patients with RA have to cope: pain and functional disability, fatigue, negative mood and social relationships. Adherence to RA medications significantly increased in the cognitive behavioural therapy group at 12 months follow-up assessment while adherence tended to decrease between baseline and follow-up visit in the control condition.

However, two others RCTs showed negative results. In both studies, non-adherent patients with RA using DMARDs were randomly allocated to an intervention arm (motivational interviewing-guided group sessions).

### Table 1

| Author                  | Condition       | Study design               | Type of intervention/Adherence assessment                      | Result                                                                 |
|-------------------------|-----------------|----------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------|
| Ferguson et al, 201525  | RA 18 patients  | RCT, 3 months              | ► Cognitive behavioural vs usual care                          | No significant difference between IG and CG                             |
|                         |                 |                            | ► MARS and Morisky                                             |                                                                       |
| Feldman et al, 201626   | RA and SLE 59   | Non-randomised, non-controlled study, 6 months | ► Cognitive behavioural vs usual care                          | At 6 months, there were no significant change in MMAS-8              |
|                         |                 |                            | ► Morisky (MMAS-8)                                             |                                                                       |
| Durcan et al, 201527    | SLE 714 patients| Prospective non-controlled cohort study | ► Multicomponent                                               | Proportion of patients with HCQ blood levels > 500 ng/mL increased from 56% at baseline to 80% in patients who had 3 or more visits |
|                         |                 |                            | ► HCQ blood levels                                              |                                                                       |
| Barton et al, 201628    | RA 166 patients | RCT, 6 months              | ► Shared decision making vs usual care                          | No significant difference between IG and CG                             |
|                         |                 |                            | ► Self report (validated single-item measure)                   |                                                                       |
| Lofland et al, 201729   | RA, PsA and chronic inflammatory bowel diseases 306 patients | Cohort study, 6 months | ► Shared decision making vs usual care                          | At 6 months, mean MMAS-4 was 0.17 in IG vs 0.41 in CG (p=0.001)       |
|                         |                 |                            | ► Morisky (MMAS-4)                                             |                                                                       |
| Nota et al, 201630      | RA and SpA 123 patients | Non-randomised study, 24 months | ► Shared decision making vs usual care                          | No significant difference between IG and CG                             |
|                         |                 |                            | ► Shared decision making vs usual care                          |                                                                       |
|                         |                 |                            | ► Morisky (MMAS-4)                                             |                                                                       |
| Van den Bermt et al 2011 | RA 50 patients | Prospective cohort study | ► Making the rheumatologist aware of patients’ non-adherence CQR | Making the rheumatologist aware of patients’ non-adherence did not improve medication adherence |

CG, control group; CQR, Compliance Questionnaire Rheumatology; HCQ, hydroxychloroquine; IG, intervention group; MARS, Medication Adherence Report Scale; MAQ, Medication Adhesion Questionnaire; MMAS, Morisky Medication Adherence Scale; PDC, proportion of days covered; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RCT, randomised controlled trial; SLE, systemic lupus erythematosus; SLR, systematic literature review; SpA, spondyloarthritis.
or to a control arm. These two studies did not demonstrate superiority of cognitive behavioural therapy by motivational interviewing over usual care to improve medication adherence. In a non-randomised study in RA and SLE, motivational interviewing by phone every 2–4 weeks did not enhance medication adherence at 6 months (table 1).

### Multicomponent interventions

No RCT evaluating multicomponent interventions was selected. In a prospective cohort study in patients with SLE, HCQ blood levels were measured every 4 months and if patients had a low blood level (<500 ng/mL), they received an email asking not to forget to take their pills and were counselling on HCQ adherence at their next encounter. The proportion of adherent patients increased with each visit from 56% at first HCQ measure to 80% in those who had 3 visits or more traducing a benefit of this multicomponent intervention on adherence to HCQ in patients with SLE (table 1).

### Other interventions

A pilot RCT assessed the efficacy of an adapted low literacy medication guide and decision aid to improve medication adherence in patients with RA who belonged to vulnerable population. Although this shared decision-making process was acceptable and improved knowledge among these patients with RA, it did not increase medication adherence. In a cohort study of patients with RA or PsA who started a biological treatment, a validated questionnaire was given to the patients in order to determine if the choice of treatment had been made with a shared decision-making process or not. Results at 6 months showed that patients who had been involved in a shared decision-making for biological therapy selection were more adherent to their biologic treatment than patients for whom treatment had been chosen only by the physician. However, a post-test study with a historical comparison group in patients with RA and SpA treated with DMARDs did not demonstrate the efficacy of a web-based patient decision aid to improve medication adherence which was a secondary outcome in this study (table 1).

### DISCUSSION

Medication adherence is a central problem in the management of chronic inflammatory rheumatic diseases. This systematic literature review highlights that educational interventions have been the most studied and have the highest level of evidence. However, it is worth noticing that an important heterogeneity exists between the studies across the modalities of these educational interventions: in some studies, interventions only consisted on an oral information on the disease and the treatment whereas in other studies interventions were designed as repeated individual or collective structured programs which certainly may have a different impact on patient adherence to treatment. Furthermore, the actors of these educational interventions were different between the studies (physicians, pharmacists, nurses and so on). Cognitive-behavioural interventions have been proposed more recently. These interventions based on motivational interviewing are inspired from psychiatry. They have shown poor results in the selected studies with only one positive RCT and two negative RCTs. These negative results could be explained by the fact that the interventions were processed in group of patients who were all considered to be non-adherent to treatment. Indeed, motivational interviewing is usually an individual procedure. Nevertheless, these techniques seem to be of interest and need further prospective evaluation. They may be integrated into educational programs. As far as lupus is concerned, it has been shown that dosing HCQ blood levels and discussing the results of these levels with the patient, especially if they are low, was effective to improve adherence to HCQ whereas simple cellular text messaging reminders without HCQ dosing was not sufficient to enhance adherence of patients with SLE. Medication reminders such as pill containers, calendars or diaries have been studied in only one non-randomised study in RA. In this study, these behavioural interventions seemed to be useful, especially in situations at high risk of oversight. Finally, our review highlights the importance of shared decision-making when a physician wants to introduce a new treatment to his patient. It has been shown that when the decision is shared between the physician and the patient, medication adherence is higher. In our review, written or web-based medication decision aid did not help for medication adherence.

Results of our systematic literature review are in concordance with data published in other non-rheumatological chronic disorders such as type 2 diabetes in which medication adherence is particularly important. Indeed, in this metabolic disease, interventions which have been shown to improve medication adherence are multicomponent interventions with a great place for educational interventions.

Our study has strengths and weaknesses. To our knowledge, this is the first systematic literature review on interventions to improve medication adherence in a large panel of chronic inflammatory rheumatic conditions. After reviewing 1325 publications, 22 studies had analysable data. This is due to the fact that many studies did not report the effect of an intervention on medication adherence. Moreover, a large number of studies we found did not treat on medication adherence but on retention rate which is not the same topic. Unfortunately, we could not calculate effect sizes and a good quality meta-analysis could not be made due to the heterogeneity of the designs of the studies. Despite we found only 13 RCTs, the majority of the non-randomised studies had a control group and we have thereby an idea of the effect of some interventions on medication adherence. However, the main disease studied was RA and there is a lack of evidence on the effect of such interventions on adherence in the other chronic rheumatisms.
Despite the importance of medication adherence in clinical practice in the management of patients suffering from chronic inflammatory rheumatic disorders, evidence on interventions to improve medication adherence is scarce. Educational interventions have been evaluated in a few studies but these studies are heterogeneous and the results are unsatisfactory. These disappointing results might have several potential explanations; perhaps interventions are not targeting the right patients; perhaps the interventions are not sufficiently tailored. Perhaps also non-adherence, due to its multifactorial nature, is difficult to act on.\textsuperscript{10–14} Overall, non-pharmacological interventions pose specific methodological problems; thus, the mitigated results of trials should be interpreted with caution.\textsuperscript{35} However, this systematic literature review points out the importance of the direct intervention between the healthcare providers at multiple levels in order to improve medication adherence. Indeed, all health professionals are involved in adherence. In particular, on top of rheumatologists, healthcare teams including nurses are important. Pharmacists will increasingly be involved as well. Advice by pharmacists on drug adherence, both in rheumatology and in other chronic disease management has been shown to promote drug adherence.\textsuperscript{15–17} In particular, on top of rheumatologists, healthcare teams all health professionals are involved in adherence. In particular, on top of rheumatologists, healthcare teams including nurses are important. Pharmacists will increasingly be involved as well. Advice by pharmacists on drug adherence, both in rheumatology and in other chronic disease settings.\textsuperscript{36, 37} The role of pharmacists may vary of course, both in rheumatology and in other chronic disease management has been shown to promote drug adherence, both in rheumatology and in other chronic disease settings.

**REFERENCES**

1. World Health Organisation. Adherence to long-term therapies: evidence for action. Geneva, WHO; 2003.
2. de Klerk E, van der Heijde D, Landewé R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44–54.
3. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology 2005;44:762–7.
4. de Thurah A, Nergaard M, Johansen MB, et al. Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheumatol 2010;39:197–205.
5. Harley CR, Frytak Jr, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(Suppl):S136–43.
6. Tkacz J, Ellis L, Bolge SC, et al. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 2014;36:737–47.
7. Brody JE. The New-York Times. 2017.
8. Palacios-Ramos V, Contreras-Yañez I, Villa AR, et al. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther 2009;11:R26.
9. Greenley RN, Kunz JH, Walter J, et al. Practical strategies for enhancing adherence to treatment regimens in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1534–45.
10. http://handbook.cochrane.org/
11. Ravindran V, Jadhav R. The effect of rheumatoid arthritis disease education on adherence to medications and followup in Kerala, India. J Rheumatol 2013;40:1460–1.
12. Clifford S, Balgouris C, Elliott R, et al. Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci 2006;28:165–70.
13. Zhang X, Tian Y, Li J, et al. Effect of targeted nursing applied to SLE patients. Exp Ther Med 2016;11:2209–12.
14. Brus HL, van der Laar MA, Taal E, et al. Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann Rheum Dis 1998;57:146–51.
15. Helliwell PS, O'Hara M, Holdsworth J, et al. A 12-month randomized controlled trial of patient education on radiographic changes and quality of life in early rheumatoid arthritis. Rheumatology 1999;38:303–8.
16. Unk JA, Brasington R. Efficacy study of multimedia rheumatoid arthritis patient education program: Multimedia rheumatoid arthritis patient education program. J Am Assoc Nurs Pract 2014;26:370–7.
17. Homer D, Nightingale P, Unkel JA, et al. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm 2010;16:833–804.
18. Fields TR, Rifaat A, Yee AMF, et al. Pilot study of a multidisciplinary outpatient patient education and monitoring program. Semin Arthritis Rheum 2017;46:601–8.
19. van der Vaart R, Drossaert CH, Taal E, et al. Impact of patient-accessible electronic medical records in rheumatology: use, satisfaction and effects on empowerment among patients. BMC Musculoskeletal Disord 2014;15:102.

**Author affiliations**

1Rheumatology Department, Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
2Paris Descartes University, Paris, France
3Sorbonne University, Paris, France
4Rheumatology Department, Centre Hospitalier Universitaire Grenoble Alpes, Hôpital Sud, Echirolles, France
5Rheumatology Department, Pitié Salpêtrière Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
6Rheumatology Department, Sainte Marguerite Hospital, Assistance Publique–Hôpitaux de Marseille, Marseille, France
7Rheumatology Department, Hôpitaux de Rouen, Rouen, France
8Rheumatology Department, Saint-Antoine Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
9Pharmacy Department, Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
10Paris Descartes University, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France

**Acknowledgements** This study was conducted thanks to an unrestricted grant from ABBVIE France (Rencontres d’Experts en Rhumatologie program). The authors thank Margaux Orange for logistic assistance.

**Contributors** All the authors contribute to the study conduction and design. ML wrote the manuscript.

**Funding** This initiative was financially supported by ABBVIE France, and all authors received honoraria from ABBVIE France to participate at this initiative. The sponsor did not play any role in the design, conduction, analysis or writing processes of this study.

**Competing interests** None declared.

---

**Patient consent** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** There are no unpublished data.

**Open access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s)) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

---

Lavielle M, et al. RMD Open 2018;4:e000684. doi:10.1136/rmdopen-2018-000684
21. Ting TV, Kudalkar D, Nelson S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. *J Rheumatol* 2012;39:174–9.

22. Bruera S, Lopez-Olivo MA, Barbo A. Use of medication reminders in patients with rheumatoid arthritis. *Value Health J Int Soc Pharmacoeconomics Outcomes Res* 2014;17:A384.

23. Evers AW, Kraaimaat FW, van Riel PL, et al. Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. *Pain* 2002;100(1-2):141–53.

24. Zwijker HE, van den Ende CH, van Lankveld WG, et al. Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: a randomized controlled trial. *Patient Educ Couns* 2014;94:356–61.

25. Ferguson A, Ibrahim FA, Thomas V, et al. Improving medication adherence in rheumatoid arthritis (RA): a pilot study. *Psychol Health Med* 2015;20:781–9.

26. Feldman C, Wohlforth A, Campos A. Use of Rheumatology-specific patient navigators for DMARD adherence: results from a pilot intervention. 2016.

27. Durcan L, Clarke WA, Magder LS, et al. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. *J Rheumatol* 2015;42:2092–7.

28. Barton JL, Trupin L, Schillinger D, et al. Use of low-literacy decision aid to enhance knowledge and reduce decisional conflict among a diverse population of adults with rheumatoid arthritis: results of a pilot study. *Arthritis Care Res* 2016;68:889–98.

29. Lofland JH, Johnson PT, Ingham MP, et al. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. *Patient Prefer Adherence* 2017;11:947–58.

30. Nota I, Drossaert CH, Tiel E, et al. Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs. *Arthritis Res Ther* 2016;18:252.

31. Sapkota S, Brien JA, Greenfield JR, et al. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes-components of interventions. *PLoS One* 2015;10:e0128581.

32. Fung V, Graetz I, Reed M, et al. Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. *PLoS One* 2018;13:e0191817.

33. Kvarnström K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a qualitative study with general practitioners. *BMJ Open* 2018;8:e015332.

34. Suh YS, Cheon YH, Kim HO, et al. Medication nonadherence in Korean patients with rheumatoid arthritis: the importance of belief about medication and illness perception. *Korean J Intern Med* 2018;33:203–210.

35. Page MJ, Boutron I, Hansen C, et al. Assessing risk of bias in studies that evaluate health care interventions: recommendations in the misinformation age. *J Clin Epidemiol* 2018;97:133–6.

36. Ryan R, Santesso N, Lowe D, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev* 2014;4:CD007768.

37. Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, et al. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. *J Hypertens* 2017;35:178–87.

38. Bosworth HB, Zullig LL, Mendys P, et al. Health information technology: meaningful use and next steps to improving electronic facilitation of medication adherence. *JMIR Med Inform* 2016;4:e9.

39. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. *Ann Rheum Dis* 2001;60:869–75.

40. van den Bernt BJ, den Broeder AA, van den Hoogen FH, et al. Making the rheumatologist aware of patients’ non-adherence does not improve medication adherence in patients with rheumatoid arthritis. *Scand J Rheumatol* 2011;40:192–6.